Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07674823 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study Of KITE-753 in R/R B-Cell ALL
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07674823: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07674823 is a Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07674823, a Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the recommended dose of KITE-753 in patients with relapsed/refractory B-cell ALL. The safety of KITE-753 will also be studied.
Interventions
- DRUG KITE-753
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-12-31 |
| Est. Completion | 2031-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07674823
The ClinicalTrials.gov registry entry for NCT07674823 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KITE-753 is the first listed.
NCT07674823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07674823 about?
NCT07674823 is a clinical study titled "Phase 1 Study Of KITE-753 in R/R B-Cell ALL". The goal of this clinical research study is to find the recommended dose of KITE-753 in patients with relapsed/refractory B-cell ALL. The safety of KITE-753 will also be studied.
What is the current status of trial NCT07674823?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-12-31. Estimated completion is 2031-04-01.
What interventions are being tested in trial NCT07674823?
The interventions under investigation include: KITE-753 (DRUG).
Who is sponsoring clinical trial NCT07674823?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.